So we having a lot of good results, a lot of good acceptance by hospitals that are contracted by DaVita, but they want to do ultrafiltration. And for reasons they have capital budget issues or nursing staff issues. So they feel that the collaboration with Nuwellis and DaVita, will fit their needs appropriate. Second part of your question about the impact in Q2, well the idea is that DaVita would buy the consoles and the circuits, as we start treating patients in the hospitals.
Anthony Vendetti: Okay, so they’ll start actually purchasing them. You mentioned a contract — contract amendment, Nestor. Does DaVita has a certain contract with their customers? And the amendment to add in ultrafiltration, is that just a small amendment that they add in? What would that look like? Did they have to agree to purchase? Could they rent? Is there a lot of flexibility there? Or are you attempting to standardize it with DaVita and their customers?
Nestor Jaramillo: Yeah. Good question, Anthony. The answer to those questions is what we plan to obtain with this pilot. So right now, DaVita has contracted hospitals to do dialysis, so they would have to amend those contracts to do ultrafiltration. DaVita will buy the product from us, and they will provide the services to their patients with their own clinical staff. So what I assume is and what we are all assuming, is that the hospital would pay a per patient fee to DaVita for treating those patients for ultrafiltration. But DaVita will take care of the rest.
Anthony Vendetti: Okay, great. That’s very helpful.
Nestor Jaramillo: Yeah. And that’s the benefit for the hospital. Hospitals that are having some capital budgets or nursing staff, this is a viable way for them to treat ultrafiltration patients.
Anthony Vendetti: And then a follow-up on the difference between that and maybe SeaStar’s SCD device for pediatrics. So is that a similar situation where you purchased from SeaStar, and then you sell that device either — what your ultrafiltration device for separately, depending on what the customer’s looking for?
Nestor Jaramillo: Correct. We would purchase the product from SeaStar and then we will sell it to the customers with our ultrafiltration services. But let me just say — clarify something here too. Our new pediatric dedicated device would be a CRRT device. That’s the device that would be a pair with SeaStar’s device right now. Right now, when we start selling the SeaStar device, that would be to use with their own CRRT devices that the hospitals would already have.
Anthony Vendetti: I see. So your new continual replacement immunotherapy device is what you’ll pair with the SCD device. But right now, until that device is available, the hospitals are using whatever device they have for CRRT.
Nestor Jaramillo: Correct. Right now, in the market there is only adult CRRT devices being used in these pediatric patients. So the SeaStar device will be used with any CRRT device currently used to treat this patient, but they all adult. When we introduce our pediatric dedicated CRRT device together with the SeaStar device, will be a much better therapy for these patients. This is why we believe, as well as many pediatric nephrologists that this is going to change the game.
Anthony Vendetti: Game changer yeah, sounds like a good partnership.
Nestor Jaramillo: Correct.
Anthony Vendetti: I just wanted to say, you mentioned two — did you mention two to three new products? This being one of them. Were there others that you could talk about or not at this time?
Nestor Jaramillo: Yes. Good observation, Anthony. We have three new products that we are going to be introducing in the next two years. Starting with the SeaStar device, that’s one. We also introducing very soon an additional catheter — venous catheter to be used with our Aquadex system. And then mid-2025, we plan to commercialize the pediatric dedicated CRRT device. So those are the three devices in the next two years.
